IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024

Aggregated presentation by day and by market

Purchases of own shares from July 1st to 5th 2024
       
Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)
IPSEN549300M6SGDPB4Z94P1101/07/2024FR00102591504 400114,6643XPAR
IPSEN549300M6SGDPB4Z94P1101/07/2024FR00102591501 600114,6941CEUX
IPSEN549300M6SGDPB4Z94P1102/07/2024FR00102591505 000113,7584XPAR
IPSEN549300M6SGDPB4Z94P1102/07/2024FR00102591502 000113,7221CEUX
IPSEN549300M6SGDPB4Z94P1103/07/2024FR00102591509 372112,9871XPAR
IPSEN549300M6SGDPB4Z94P1103/07/2024FR00102591504 093112,9235CEUX
IPSEN549300M6SGDPB4Z94P1103/07/2024FR0010259150300112,6383TQEX
IPSEN549300M6SGDPB4Z94P1103/07/2024FR0010259150235112,5774AQEU
IPSEN549300M6SGDPB4Z94P1104/07/2024FR00102591507 091114,1958XPAR
IPSEN549300M6SGDPB4Z94P1104/07/2024FR00102591502 909114,1684CEUX
IPSEN549300M6SGDPB4Z94P1105/07/2024FR00102591507 561111,8557XPAR
IPSEN549300M6SGDPB4Z94P1105/07/2024FR00102591503 353111,7468CEUX
IPSEN549300M6SGDPB4Z94P1105/07/2024FR0010259150838111,8063TQEX
IPSEN549300M6SGDPB4Z94P1105/07/2024FR0010259150558111,8204AQEU
   TOTAL49 310 113,2432 

Attachment



EN
09/07/2024

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Cabometyx® approved in the EU for previously treated advanced neuroend...

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2Approval based on pivotal CABINET Phase III trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors, respectively3,4 PARIS, FRANCE, 24 July...

July 24, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines a...

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées Cabometyx® est le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines non résécables ou métastatiques précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’administration ou non d’un traitement systémique auparavant, autre qu’un traitement par analogue de la somatostatine1,2.Approbation basée sur l’essai pivotal de Phase III CABINET qui a démontré une réduction de 77 % et 62 % du risque de progression...

July 24, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen announces changes to its Executive Committee

Ipsen announces changes to its Executive Committee PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product OfficerAndreas Gerber is appointed to EVP, Head of InternationalCaroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the Internat...

July 23, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen annonce des changements au sein de son Comité Exécutif

Ipsen annonce des changements au sein de son Comité Exécutif PARIS, FRANCE, 23 juillet 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, annonce aujourd'hui les changements suivants au sein de son Comité Exécutif : Mari Scheiffele est nommée Vice-Présidente Exécutive, Directrice des Produits.Andreas Gerber est nommé Vice-Président Exécutif, Directeur International.Caroline Sitbon est nommée Vice-Présidente Exécutive, Directrice Juridique. Mari, Andreas et Caroline reporteront à David Loew, Directeur Général d'Ipsen, à compter du 1er septembre 2025. ...

July 23, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025 Aggregated presentation by day and by market Statement of transactions in own shares from July 14th to July 18th 2025        Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1114/07/2025FR0010259150 240 105,775AQEUIPSEN549300M6SGDPB4Z94P1114/07/2025FR0010259150 706 105,86459CCXEIPSEN549300M6SGDPB4Z94P1114/07/2025FR00...

July 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch